|
NEW YORK--(BUSINESS WIRE)--
Pluristem Therapeutics, Inc. (OTCBB:PSTI),
a leading bio-therapeutics company dedicated to the commercialization of
non-personalized (allogeneic) cell therapy products for a variety of
malignant, ischemic and autoimmune disorders, announced today that it
has been chosen to present at the Annual Meeting of the American Society
of Hematology (ASH) on December 8, 2007 in Atlanta, Georgia. Hematology
experts from around the world will gather to discuss the latest
developments in their field.
Dr. Moran Meiron, Research Director of
Pluristem, will present pre-clinical results that demonstrate the
potential of human placental-derived mesenchymal stromal cells (MSCs),
grown in a 3D culture and termed PLacental eXpanded (PLX-BMT) cells, to
promote the engraftment of CD34+ human umbilical cord blood (hUCB) cells
in patients afflicted with leukemia and other hematological
malignancies. The study suggests that co-transplantation of PLX-BMT may
improve engraftment when using hUCB as the source of hematopoietic stem
cells (HSCs).
Zami Aberman, Pluristem's President & CEO
states, "Our ability to improve the engraftment of hUCB in the treatment
of severe blood disorders, as will be presented by Dr. Meiron at the ASH
conference in Atlanta, has attracted the attention of the hematology
community. We are honored to have been chosen to present at this meeting
of prestigious hematology experts. Our revolutionary 3D expansion
process could lead to a wider use of hUCB cells in treating various
types of blood cancer and potentially benefiting up to 100,000 patients
annually."
About Pluristem
Pluristem Therapeutics, Inc. is a Company
dedicated to the commercialization of non-personalized (allogeneic) stem
cell therapy products for the treatment of numerous severe degenerative,
malignant and autoimmune disorders. The Company's first product, PLX-BMT,
is directed at resolving the global shortfall of matched tissue for bone
marrow transplantation (BMT) by improving the engraftment of
hematopoietic stem cells (HSCs) contained in umbilical cord blood (UCB).
Pluristem's products are derived from
mesenchymal stromal cells (MSCs) obtained from the placenta and not from
embryonic stem cells. They are expanded in the Company's proprietary
PluriX(TM) 3D bioreactor that imitates the natural microstructure of
bone marrow and does not require supplemental growth factors, cytokines
or other exogenous materials. Pluristem believes the resultant expanded
cells, termed PLX cells, are multi-potent and able to differentiate into
a variety of cell types. Recent evidence also suggests their efficacy
may be related to their secretion of cytokines or other potent immune
modulators. Furthermore, PLX cells are believed to be immune-privileged,
hence protecting the recipient from immunological reactions that often
accompany transplantation.
Pluristem has offices in the USA with
research and manufacturing facilities in Israel.
Safe Harbor Statement
This press release contains
forward-looking statements within the meaning of the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995 and
federal securities laws. These forward-looking statements are based on
the current expectations of the management of Pluristem only, and are
subject to a number of factors and uncertainties that could cause actual
results to differ materially from those described in the forward-looking
statements. For example, when we speak about our revolutionary 3D
expansion process and say it could lead to a wider use of hUCB cells in
treating various types of blood cancer and potentially benefiting up to
100,000 patients annually, we are using forward-looking statements. The
following factors, among others, could cause actual results to differ
materially from those described in the forward-looking statements:
changes in technology and market requirements; our technology may not be
validated as we progress further and our methods may not be accepted by
the scientific community; we may be unable to retain or attract key
employees whose knowledge is essential to the development of our
products; unforeseen scientific difficulties may develop with our
process; results in the laboratory may not translate to equally good
results in real surgical settings; our patents may not be sufficient;
our products may harm recipients; changes in legislation; inability to
timely develop and introduce new technologies, products and
applications; loss of market share and pressure on pricing resulting
from competition, which could cause the actual results or performance of
Pluristem to differ materially from those contemplated in such
forward-looking statements. Except as otherwise required by law,
Pluristem undertakes no obligation to publicly release any revisions to
these forward-looking statements to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated
events. For a more detailed description of the risk and uncertainties
affecting Pluristem, reference is made to Pluristem's reports filed from
time to time with the Securities and Exchange Commission.
For more information visit our website at
www.pluristem.com, the content of which is not part of this press
release.
Source: Pluristem Therapeutics, Inc. |
